New hope for lung cancer patients when first targeted drug stops working
NCT ID NCT07199010
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how well the drug taletrectinib works in people with advanced ROS1-positive non-small cell lung cancer whose cancer has gotten worse after treatment with entrectinib. Researchers will follow 50 patients in real-world clinics to see if the drug shrinks tumors and how long it keeps the cancer under control. The goal is to gather practical information on effectiveness and safety outside of a strict clinical trial setting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Taletrectinib (a targeted cancer drug)
- What this could lead to
- If it works, this could offer a new treatment option for people with a specific type of lung cancer that has stopped responding to an earlier drug.
- What could go wrong
- This is an early, small observational study (50 people) that just watches what happens in real-world practice. It may not prove the drug works better than other options, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai East Hospital (The East Hospital Affiliated to Tongji University)
Shanghai, Shanghai Municipality, 200120, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.